Chief Scientific Officer of Lilly: A Major Breakthrough in Alzheimer's Disease is Coming, Like a Weight Loss Drug
芊芊551
发表于 2023-11-7 18:45:35
311
0
0
Dr. Daniel Skovronsky, Chief Scientific Officer of Lilly, the world's most valuable pharmaceutical company, stated with extreme optimism that a major breakthrough in the treatment of Alzheimer's disease is imminent and that the drug being developed may become the next hot spot similar to the weight loss miracle drug "GLP-1".
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- The review results of Supermicro Computer did not find any inappropriate behavior and decided to replace the Chief Financial Officer
- OpenAI poaching cryptocurrency company Coinbase hires its first Chief Marketing Officer
- OpenAI hires former Coinbase executive as Chief Marketing Officer
- Alphabet Chief Investment Officer: Google's biggest bet is to introduce artificial intelligence into search
- Former head of user development department at Jiyue Motors joins Starbucks as Chief Growth Officer
- Eli Lilly's Alzheimer's disease therapy, Minolta (Donaimab Injection), has been approved in China
- Eli Lilly's Alzheimer's disease treatment with donentinumab injection approved
- Eli Lilly's Alzheimer's disease therapy, Minolta (Donaimab Injection), has been approved in China
- Boeing appoints Chief Communications Officer
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy
